A dentist's warning on the CBS6 Morning Show has flagged oral health damage as a lesser-known potential downside of GLP-1 weight-loss drugs such as Ozempic. The segment, reported by WRGB's Emma Quinn, acknowledged the drugs are a legitimate, effective treatment while raising an unquantified safety…
A dentist's warning on a regional morning television show has added an unfamiliar question to the risk discussion around GLP-1 weight-loss drugs: what the medications do to teeth and gums. Dr. David Kavangh of Columbia Family Dentistry told the CBS6 Morning Show that GLP-1 drugs such as Ozempic may deliver meaningful weight-loss improvements but carry potential oral health risks. The segment framed oral health damage as a lesser-known potential downside of the class, while Kavangh stressed that the drugs are a legitimate, effective treatment and that Ozempic is surrounded by myths.
WRGB reporter Emma Quinn wrote up the segment for the station. The warning is not a study, and it carries none of the statistical apparatus of one. But it arrives at a moment when GLP-1 receptor agonists are the latest trend in weight loss, which means a clinician's observation about teeth can reach a large audience of current and prospective patients quickly.
For peptide researchers, the claim has a specific relevance. GLP-1 receptor agonists are peptide-based therapies, and the warning is a clinician-reported safety signal involving oral health that neither the segment nor the accompanying report quantifies. It is, in effect, a hypothesis offered in public that formal investigation will have to confirm or refute.
The claims Kavangh made are straightforward. GLP-1 drugs are the latest trend for weight loss. They may be a legitimate treatment, with meaningful improvements for patients who take them. But they also have the potential for underlying issues when it comes to teeth and oral health. He joined the show to discuss Ozempic myths and how the medications can affect oral health.
The written report contains none of the supporting detail that would normally accompany a clinical warning. It provides no specific statistics, no study citations, and no clinical evidence. It does not describe which oral health conditions Kavangh has in mind, nor the mechanism by which the drugs might harm teeth. It does not identify the Ozempic myths he addressed.
The report also leaves open the scope of the warning. It does not state whether the oral health risk applies to all GLP-1 drugs or only to Ozempic, the brand name for semaglutide. That distinction matters, because a drug-specific effect would point to the molecule, while a class-wide effect would implicate the mechanism that all GLP-1 receptor agonists share.
Glucagon-like peptide-1 is an incretin hormone , a short peptide secreted by intestinal L cells after meals. It amplifies glucose-dependent insulin release, suppresses glucagon, slows gastric emptying, and acts on the central nervous system to reduce appetite. GLP-1 receptor agonists are engineered peptides that resist the rapid degradation that normally limits the native hormone's half-life, and they have become a cornerstone of type 2 diabetes and obesity treatment. Ozempic, the drug named in the segment, is semaglutide .
Kavangh did not describe a mechanism, but the pharmacology of the class offers several plausible routes to oral harm, and these shape what a formal investigation should measure. The first is salivary flow. Reduced food intake, nausea, and reported dry mouth can cut saliva production, and saliva is the mouth's primary buffer, lubricant, and antimicrobial defense. A persistently dry mouth is a well-established risk factor for dental caries.
The second route is acid exposure. Nausea and vomiting are common adverse effects of GLP-1 receptor agonists, and repeated vomiting brings gastric acid across the teeth, eroding enamel. Delayed gastric emptying, a direct pharmacologic effect of the class, can also feed reflux symptoms. The third route is nutritional and microbial change: rapid weight loss alters diet composition, and shifts in the oral microbiome are plausible but under-studied in this population. Each route is testable, and each predicts a different signature in the mouth, which matters for designing the right study.
As a piece of evidence, the warning is a single clinician's public statement. It does not establish that GLP-1 drugs cause oral health damage, and it does not establish the direction of any association. It does establish that a practicing dentist sees enough, or anticipates enough, to raise the concern in public, and that is how many safety signals begin: with an observant clinician who notices a pattern.
The usual machinery for testing such a signal is worth contrasting with what the segment offers. Randomized controlled trials of weight-loss drugs are powered on metabolic endpoints and rarely include dental examinations, so subtle oral effects can escape them. Post-market surveillance systems such as the FDA Adverse Event Reporting System depend on spontaneous reports, and patients do not routinely connect dental complaints to an injectable weight-loss drug.
That gap explains why the segment matters despite its thin evidence. It surfaces a hypothesis in a form that researchers, clinicians, and regulators can act on: prospective dental assessments in ongoing GLP-1 trials, dental endpoints in new trials, and retrospective analyses of dental claims among GLP-1 users. Until such data exist, the claim remains unverified, which is precisely why the open questions are consequential.
For researchers, the warning argues for making oral health a measured outcome rather than an anecdote. A prospective substudy could include standardized dental examinations at baseline and follow-up, salivary flow measurement, enamel erosion scoring, and oral microbiome sampling in patients starting GLP-1 therapy. The mechanisms sketched above predict specific findings: reduced salivary flow, erosion patterns from acid exposure, and microbial shifts, each of which can be quantified.
For prescribers, the practical step is to ask. Clinicians managing obesity or diabetes with GLP-1 therapy should ask patients about dry mouth, heartburn, vomiting, and dental symptoms, and should coordinate with dental providers. For dentists, the step is to record GLP-1 use in patient histories and to look for erosion and caries patterns in patients taking the drugs.
Patient education is the third leg. The segment itself acknowledged the balance: GLP-1 drugs are a legitimate, effective treatment for weight loss, and the oral health question is an additional consideration, not a reason to avoid therapy. Education materials should address oral health alongside weight-loss efficacy, covering hydration, saliva substitutes, acid exposure after vomiting, and routine dental care.
GLP-1 receptor agonists are among the most commercially consequential peptides in medicine, and the supply chain that produces them, from peptide synthesis and formulation to fill-finish and distribution, is built around a class with enormous and growing demand. A safety signal touches that chain at several points: pharmacovigilance teams, package inserts, risk communication, and, if the signal were confirmed, label changes and monitoring requirements.
The class-level question is the one developers most need answered. Ozempic is semaglutide, one member of the GLP-1 receptor agonist family, which also includes liraglutide and combination peptides that add other incretin hormones, all peptide-based. If the oral health risk is class-wide, it implicates the shared mechanism; if it is semaglutide-specific, it implicates the molecule. The segment does not say which, and neither does the existing evidence base.
A third point concerns where safety information originates. This signal did not come from a trial data safety monitoring board or a regulatory database; it came from a dentist on a morning television show. That is a reminder that adverse effects of peptide therapies can surface far from metabolic medicine, and that the chain from clinic to regulator depends on individual clinicians recognizing an unfamiliar pattern and saying so publicly.
The most direct open question is clinical: which specific oral health conditions did Kavangh link to GLP-1 drug use? The report does not say. It also does not identify the Ozempic myths he addressed during the segment, an omission that matters because the segment's credibility rested partly on separating myths from real risks.
Two scope questions follow. Is the oral health risk specific to Ozempic or common to the entire GLP-1 class? What evidence underlies the warning: clinical observations from Kavangh's own practice, case reports, or published studies? The report provides none of that. It also gives no air date for the segment and no publication date for the written report, and it spells the dentist's name "Kavangh," which may be a typographical error.
Each question has a method that would settle it. Prospective dental assessments in GLP-1 clinical trials, including baseline and follow-up dental examinations and salivary metrics, would test the hypothesis directly. Registry and claims-based studies comparing dental outcomes among GLP-1 users against matched controls would measure the effect in real-world populations. Systematic capture of dental adverse events in post-market surveillance would show whether the signal generalizes. Until one of those is done, the correct position is the one Kavangh himself took: the drugs are a legitimate, effective treatment for weight loss, and the oral health question is a lesser-known potential downside that now requires evidence.
Peptides referenced: Semaglutide, Liraglutide, Glucagon, GLP-1.
Related reading: Copper Peptides Go Mainstream in Skin Care as GHK-Cu Leads the Field, Oral Wegovy Outruns Foundayo in the First Full Quarter of Oral Competition, UK First in Europe to Approve Lilly's Oral GLP-1 Pill Foundayo, Federal pilot caps Medicare GLP-1 weight-loss copays at $50.